Published July 3, 2018
| Version v1
Dataset
Open
The process of HDAC11 Assay Development: Effect of DMSO
Description
For the purpose of compound library screenings, the compounds would be made available in DMSO and thus, when they would be incubated with the protein, the protein solution will now contain DMSO as well. It is important to determine the concentration of DMSO that could be tolerated by the protein such that the protein stays active. Hence, the effect of varying concentration of DMSO was analyzed on HDAC11 activity.
Notes
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
3july2018-HDAC11-DMSO.pdf
Files
(92.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:605a0fab1a966afd12bb671f72f98c11
|
92.2 kB | Preview Download |